Table 1 Patient characteristics.
ALL (n = 207) | FP based (n = 91) | PTX based (n = 102) | IRI based (n = 14) | P-value | |
|---|---|---|---|---|---|
Age—median (range) | 66 (42–84) | 66 (42–84) | 65 (42–83) | 64 (57–77) | 0.092 |
Sex | |||||
Male | 147 (71%) | 69 (76%) | 66 (64%) | 10 (71%) | 0.251 |
Female | 60 (29%) | 22 (24%) | 36 (36%) | 4 (29%) | |
PS | |||||
0/1 | 206 (99%) | 91 (100%) | 101 (99%) | 14 (100%) | 1.000 |
2 | 1 (1%) | 0 | 1 (1%) | 0 | |
HER2 | |||||
Positive | 42 (20%) | 30 (33%) | 12 (12%) | 0 | 0.001 |
Negative | 143 (69%) | 55 (60%) | 77 (75%) | 11 (79%) | |
Unknown | 22 (11%) | 6 (7%) | 13 (13%) | 3 (21%) | |
Histology | |||||
Intestinal | 81 (39%) | 42 (46%) | 33 (29%) | 6 (43%) | 0.138 |
Diffuse | 126 (61%) | 49 (54%) | 69 (71%) | 8 (57%) | |
Metastasis site | |||||
Peritoneum | 84 (41%) | 29 (32%) | 51 (50%) | 5 (36%) | 0.032 |
Ascites | |||||
Present | 76 (37%) | 26 (29%) | 47 (46%) | 3 (21%) | 0.020 |
Number of metastatic sites | |||||
≧ 2 | 114 (55%) | 55 (60%) | 55 (54%) | 4 (29%) | 0.078 |
Time of recurrence | |||||
During adjuvant S-1 | 125 (60%) | 51 (56%) | 65 (64%) | 9 (64%) | 0.533 |
Within 6 months after adjuvant S-1 | 82 (40%) | 40 (44%) | 37 (36%) | 5 (36%) | |
